Verily just raised $300M and, more importantly, ended Alphabet’s controlling stake.

TL;DR

Verily just raised $300M and, more importantly, ended Alphabet’s controlling stake. It also formally changed its legal name to Verily Health Inc. The capital matters. The structural change matters more. In healthcare, ownership is part of the product — when you’re asking health systems and life sciences companies to trust you with sensitive data, being controlled by one of the world’s biggest tech platforms creates friction. Series X Capital led the round; UCHealth and University of Colorado Anschutz moved from strategic partner to shareholder. The real test is whether Verily can finally turn years of technical ambition into durable commercial traction, while convincing the market that its data trust story is strong enough.

Verily just raised $300M and, more importantly, ended Alphabet Inc.’s controlling stake in the business. It has also formally changed its legal name to Verily Health Inc.

The capital matters. The structural change matters more.

For a decade, Verily lived under Google/Alphabet’s umbrella as one of its earliest health moonshots. That gave it resources, talent, and patience. But in healthcare, ownership structure is not just governance. It is part of the product.

When you are asking health systems, life sciences companies, and public sector partners to trust you with sensitive data and AI infrastructure, being controlled by one of the world’s biggest tech platforms can create friction. As a personal anecdote, I immediately stopped using my Fitbit when Google took over the company. Independence does not solve that automatically, but it makes the trust story cleaner.

The investor list reinforces the point. Series X Capital led the round. Alphabet stays in as a significant minority investor, but no longer controls the company. UCHealth and the University of Colorado Anschutz also invested, moving from strategic partner to shareholder. That is a meaningful signal.

The timing is not random. Verily has been lining up partnerships that fit this next chapter: Samsung Electronics Galaxy Watch data for biomarker-driven clinical research, Salesforce Agentforce Health integration for enterprise workflows, and NVIDIA infrastructure embedded across the Pre platform. Those partnerships look more natural when Verily is positioned as an independent health AI platform, not an Alphabet-controlled asset.

There is, however, a real tension here.

Verily is trying to scale a precision health data and AI platform while still facing a pending whistleblower lawsuit from 2023. A former executive alleges that patient data in the Onduo diabetes program was misused and that internal investigators confirmed multiple violations. Verily denies the allegations, and the case is ongoing. In a health data business, allegations around privacy and governance cut straight into credibility.

That is why this move matters beyond Verily.

Alphabet may be discovering that controlling health companies can limit their strategic value. In this category, independence can make a company more investable, more “partnerable”, and maybe more credible.

The real test is whether Verily can finally turn years of technical ambition into durable commercial traction, while convincing the market that its data trust story is strong enough to support the platform it wants to become.

Key takeaways

• Verily raised $300M, but the bigger move is structural: Alphabet no longer holds a controlling stake, and the company is now formally Verily Health Inc.
• In healthcare, ownership structure is part of the product. Asking health systems and life sciences partners to trust an Alphabet-controlled entity with sensitive data creates real friction.
• Personal data point: I stopped using my Fitbit the moment Google took over. That reaction isn’t unique — it reflects how clinicians, patients, and institutional partners think about data control.
• The investor signal matters. UCHealth and University of Colorado Anschutz moving from strategic partner to shareholder is concrete institutional confidence.
• Recent partnerships (Samsung Galaxy Watch, Salesforce Agentforce Health, NVIDIA infrastructure) look more natural under an independent Verily than an Alphabet-controlled one.
• The pending whistleblower lawsuit over Onduo patient data is a live credibility risk. In a data trust business, unresolved governance allegations are not background noise.
• Alphabet may be learning that controlling health companies caps their strategic ceiling. Independence can unlock value that platform ownership forecloses.